Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.6320
+0.0344 (5.76%)
Mar 12, 2026, 1:52 PM EDT - Market open
Vistagen Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Vistagen Therapeutics stock has a target of 0.90, which predicts a 42.41% increase from the current stock price of 0.63.
Price Target: $0.90 (+42.41%)
Analyst Consensus: Hold
* Price targets were last updated on Dec 17, 2025.
Analyst Ratings
The average analyst rating for Vistagen Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 17, 2025 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 17, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $15 → $0.9 | Strong Buy → Hold | Downgrades | $15 → $0.9 | +42.41% | Dec 17, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $0.2 → $15 | Hold → Strong Buy | Upgrades | $0.2 → $15 | +2,273.42% | Dec 7, 2023 |
| Stifel | Stifel | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +1,798.73% | Nov 14, 2023 |
Financial Forecast
Revenue This Year
1.09M
from 486.00K
Increased by 124.49%
Revenue Next Year
4.95M
from 1.09M
Increased by 353.99%
EPS This Year
-1.82
from -1.67
EPS Next Year
-1.12
from -1.82
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 1.4M | 8.9M | ||||
| Avg | 1.1M | 5.0M | ||||
| Low | 784,000 | 1.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 180.9% | 718.1% | ||||
| Avg | 124.5% | 354.0% | ||||
| Low | 61.3% | 8.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -1.67 | -0.71 | ||||
| Avg | -1.82 | -1.12 | ||||
| Low | -1.89 | -1.39 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.